Literature DB >> 33381651

Alternative approach of hepatocellular carcinoma surveillance: abbreviated MRI.

Ryan L Brunsing1, Kathryn J Fowler2, Takeshi Yokoo3, Guilherme Moura Cunha2, Claude B Sirlin2, Robert M Marks4,5.   

Abstract

This review focuses on emerging abbreviated magnetic resonance imaging (AMRI) surveillance of patients with chronic liver disease for hepatocellular carcinoma (HCC). This surveillance strategy has been proposed as a high-sensitivity alternative to ultrasound for identification of patients with early-stage HCC, particularly in patients with cirrhosis or obesity, in whom sonographic visualization of small tumors may be compromised. Three general AMRI approaches have been developed and studied in the literature - non-contrast AMRI, dynamic contrast-enhanced AMRI, and hepatobiliary phase contrast-enhanced AMRI - each comprising a small number of selected sequences specifically tailored for HCC detection. The rationale, general technique, advantages and disadvantages, and diagnostic performance of each AMRI approach is explained. Additionally, current gaps in knowledge and future directions are discussed. Based on emerging evidence, we cautiously recommend the use of AMRI for HCC surveillance in situations where ultrasound is compromised.

Entities:  

Keywords:  Abbreviated magnetic resonance imaging; Hepatitis B; cirrhosis; hepatocellular carcinoma; magnetic resonance imaging; surveillance

Year:  2020        PMID: 33381651      PMCID: PMC7771881          DOI: 10.20517/2394-5079.2020.50

Source DB:  PubMed          Journal:  Hepatoma Res        ISSN: 2394-5079


  78 in total

1.  Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma.

Authors:  Robert F Hanna; Vesselin Z Miloushev; An Tang; Lee A Finklestone; Sidney Z Brejt; Ranjit S Sandhu; Cynthia S Santillan; Tanya Wolfson; Anthony Gamst; Claude B Sirlin
Journal:  Abdom Radiol (NY)       Date:  2016-01

2.  Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: An equivalence study using LI-RADS v2018.

Authors:  Gaurav Khatri; Ivan Pedrosa; Lakshmi Ananthakrishnan; Alberto Diaz de Leon; David T Fetzer; John Leyendecker; Amit G Singal; Yin Xi; Adam Yopp; Takeshi Yokoo
Journal:  J Magn Reson Imaging       Date:  2019-06-18       Impact factor: 4.813

3.  Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma.

Authors:  Hyun Jeong Park; Young Kon Kim; Min Jung Park; Won Jae Lee
Journal:  Abdom Imaging       Date:  2013-08

4.  Clinical Evaluation of Free-Breathing Contrast-Enhanced T1w MRI of the Liver using Pseudo Golden Angle Radial k-Space Sampling.

Authors:  Dennis M Hedderich; Kilian Weiss; Judith E Spiro; Daniel Giese; Gabriele M Beck; David Maintz; Thorsten Persigehl
Journal:  Rofo       Date:  2018-03-13

5.  New OPTN/UNOS classification system for nodules in cirrhotic livers detected with MR imaging: effect on hepatocellular carcinoma detection and transplantation allocation.

Authors:  Andrew B Rosenkrantz; Naomi Campbell; Natasha Wehrli; Michael J Triolo; Sooah Kim
Journal:  Radiology       Date:  2014-10-07       Impact factor: 11.105

Review 6.  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2019-07       Impact factor: 3.500

7.  Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance.

Authors:  Robert M Marks; Andrew Ryan; Elhamy R Heba; An Tang; Tanya J Wolfson; Anthony C Gamst; Claude B Sirlin; Mustafa R Bashir
Journal:  AJR Am J Roentgenol       Date:  2015-03       Impact factor: 3.959

8.  Free-breathing pediatric MRI with nonrigid motion correction and acceleration.

Authors:  Joseph Y Cheng; Tao Zhang; Nichanan Ruangwattanapaisarn; Marcus T Alley; Martin Uecker; John M Pauly; Michael Lustig; Shreyas S Vasanawala
Journal:  J Magn Reson Imaging       Date:  2014-10-20       Impact factor: 4.813

9.  Randomized controlled trial of screening for hepatocellular carcinoma.

Authors:  Bo-Heng Zhang; Bing-Hui Yang; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

10.  HCC screening: assessment of an abbreviated non-contrast MRI protocol.

Authors:  Michael Vinchill Chan; Stephen J McDonald; Yang-Yi Ong; Katerina Mastrocostas; Edwin Ho; Ya Ruth Huo; Cositha Santhakumar; Alice Unah Lee; Jessica Yang
Journal:  Eur Radiol Exp       Date:  2019-12-18
View more
  5 in total

Review 1.  Up-to-Date Role of CT/MRI LI-RADS in Hepatocellular Carcinoma.

Authors:  Guilherme Moura Cunha; Victoria Chernyak; Kathryn J Fowler; Claude B Sirlin
Journal:  J Hepatocell Carcinoma       Date:  2021-05-31

2.  Inter-reader agreement of abbreviated magnetic resonance imaging for hepatocellular carcinoma detection: a systematic review and meta-analysis.

Authors:  Dong Hwan Kim; Sang Hyun Choi; Ji Sung Lee; Joon-Il Choi
Journal:  Abdom Radiol (NY)       Date:  2021-10-11

Review 3.  Abbreviated MR Protocols for Chronic Liver Disease and Liver Cancer.

Authors:  Guillermo Carbonell; Bachir Taouli
Journal:  Magn Reson Imaging Clin N Am       Date:  2021-08       Impact factor: 1.376

Review 4.  Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound.

Authors:  Junghoan Park; Jeong Min Lee; Tae-Hyung Kim; Jeong Hee Yoon
Journal:  Clin Mol Hepatol       Date:  2021-12-27

5.  Abbreviated MRI Protocol for the Assessment of Ablated Area in HCC Patients.

Authors:  Vincenza Granata; Roberta Grassi; Roberta Fusco; Sergio Venanzio Setola; Andrea Belli; Mauro Piccirillo; Silvia Pradella; Marzia Giordano; Salvatore Cappabianca; Luca Brunese; Roberto Grassi; Antonella Petrillo; Francesco Izzo
Journal:  Int J Environ Res Public Health       Date:  2021-03-30       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.